Niacin

Evidence Level: N/A

Predicted Indications: 0

Niacin

Pharmacist Assessment Report

Niacin: Known uses and market status in India

Summary

All of the TxGNN model’s candidates for Niacin that can be traced to a source are already known uses, so there is currently no new predicted indication for this drug. The page below lists the known-use groups; no known-use items were recorded for this drug.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	0
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
151623	Nialip 250mg Tablet	strip of 7 tablets	Valid
150631	Nicoglow 250mg Tablet	strip of 10 tablets	Valid

Safety Considerations

Drug Interactions: 178 interactions were recorded. Those listed are mostly Moderate, with glucose-lowering drugs prominent: metformin, sulfonylureas (glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), GLP-1 agonists (albiglutide, dulaglutide, exenatide), DPP-4 inhibitor alogliptin, acarbose and several insulins. Interaction with acetylsalicylic acid is rated Minor. Blood glucose should be monitored when niacin is combined with these drugs.

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.